Technical Analysis for VCEL - Vericel Corporation

Grade Last Price % Change Price Change
grade D 9.39 -6.47% -0.65
VCEL closed down 6.47 percent on Friday, March 27, 2020, on approximately normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Up
Historical VCEL trend table...

Date Alert Name Type % Chg
1,2,3 Retracement Bearish Bearish Swing Setup 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
MACD Bullish Signal Line Cross Bullish 0.00%
Narrow Range Bar Range Contraction 0.00%
NR7 Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Multiple of Ten Bullish Other -6.47%
Wide Bands Range Expansion -6.47%
Up 3 Days in a Row Strength -6.47%

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:


Vericel Corporation, a commercial-stage biopharmaceutical company, focuses on developing patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. It markets two autologous cell therapy products in the United States, including Carticel (autologous cultured chondrocytes), an autologous chondrocyte implant for the treatment of cartilage defects in the knee; and Epicel (cultured epidermal autografts), a permanent skin replacement for the treatment of patients with deep-dermal or full-thickness burns comprising greater than or equal to 30 percent of total body surface area. The company is also developing MACI, a third-generation autologous chondrocyte implant for the treatment of cartilage defects in the knee; and ixmyelocel-T, a patient-specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy. The company, formerly known as Aastrom Biosciences, Inc., was founded in 1989 and is headquartered in Cambridge, Massachusetts.
Medicine Biotechnology Biopharmaceutical Medical Specialties Stem Cells Cell Therapy Burns Knee Severe Diseases

Is VCEL a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 19.95
52 Week Low 6.78
Average Volume 708,788
200-Day Moving Average 16.65
50-Day Moving Average 14.83
20-Day Moving Average 11.06
10-Day Moving Average 8.66
Average True Range 1.25
ADX 48.91
+DI 17.68
-DI 31.30
Chandelier Exit (Long, 3 ATRs ) 12.03
Chandelier Exit (Short, 3 ATRs ) 10.52
Upper Bollinger Band 16.47
Lower Bollinger Band 5.64
Percent B (%b) 0.35
BandWidth 98.01
MACD Line -1.98
MACD Signal Line -2.04
MACD Histogram 0.0541
Fundamentals Value
Market Cap 308.21 Million
Num Shares 32.8 Million
EPS -1.04
Price-to-Earnings (P/E) Ratio -9.03
Price-to-Sales 2.75
Price-to-Book 10.56
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 10.28
Resistance 3 (R3) 10.33 10.08 10.13
Resistance 2 (R2) 10.08 9.86 10.06 10.08
Resistance 1 (R1) 9.74 9.72 9.62 9.69 10.03
Pivot Point 9.49 9.49 9.43 9.47 9.49
Support 1 (S1) 9.15 9.27 9.03 9.10 8.75
Support 2 (S2) 8.90 9.13 8.88 8.70
Support 3 (S3) 8.56 8.90 8.65
Support 4 (S4) 8.51